Skip to main content

CombiMatrix Says Q3 Revenue Inches Up 2 Percent as Net Loss Widens 11 Percent

NEW YORK (GenomeWeb News) — CombiMatrix today said that third-quarter revenue increased 2 percent as net loss widened 11 percent.
 
Total receipts for the three months ended Sept. 30 rose to $1.8 million from $1.5 million during the same period last year. Most of the revenue growth was from sales of the company’s array equipment and services, which more than doubled to $1.1 million. Government contracts contributed $725 thousand
 
R&D spending increased 87 percent to $2.8 million.
 
Net loss increased 11 percent to $4.3 million from $3.9 million year over year. The company blamed the increase on non-cash stock compensation and depreciation charges, and changes in financial reporting concerning employee stock options.
 
CombiMatrix had around $8.3 million in cash, cash equivalents, and short term investments as of Sept. 30.
 
Shares in CombiMatrix were down 5.16 percent, or $.03, at $.72 in mid-afternoon trading.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.